ENDRA Life Sciences Inc.
NDRA· Nasdaq
NDRAENDRA Life Sciences Inc.
Filed May 15, 2026 · 10-Q · 45 days after period end · 0001213900-26-057680
| Metric | Q1 2026 | Q1 2025 | Q1 2024 | Q1 2023 |
|---|---|---|---|---|
| Net Income | -$1.31M | -$1.04M | -$2.78M | -$2.94M |
| EPS Diluted | -$1.09 | -$1.86 | — | — |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
ENDRA Life Sciences Inc. · CIK 1681682 · Engraved from SEC EDGAR
ended Mar 31, 2026 · filed May 15, 2026 · 45 d after period end
